Table 1.

Changes in PrPC‐FOXO3a‐KLF5 expression in metastases determine patient outcome

Patient	T/N scoring	Stage at diagnosis	Adjuvant chemotherapy	Chemotherapy for metastasis	Outcome (month)	PrPC change colon vs Met (%)	Foxo change colon vs Met (%)	KLF5 change colon vs Met (%)
1	T4a/N2	IV	NONE	mFOLFOX6	Dead (36)	−5	65	0
5	T3/N1	III	mFOLFOX6	FOLFIRI	Dead (42)	−1	60	−1
6	T3/N2	IV	NONE	mFOLFOX6	Dead (24)	−30	10	0
2	T3/N0	II	XELOX	XELOX	Dead (13)	25	−20	15
7	T3/N2	IV	mFOLFOX6	FOLFIRI	Dead (28)	0	−45	4
3	T3/N1	IV	NONE	PMC	Alive (138)	5	−15	0
4	T3/N2	IV	NONE	mFOLFOX6	Alive (14)	1	−20	9
8	T3/N0	IV	NONE	mFOLFOX6	Alive (12)	−1	−30	−9
9	T2/N0	II	NONE	TS1	Alive (96)	0	−10	−4
10	T3/N1	IV	NONE	UFT+LV	Alive (102)	5	0	−4
11	T3/N0	IV	UFT	NA	NA	5	−15	0

Light grey: poor patient outcome based on increased FOXO3a expression. Dark grey: poor patient outcome based on increased KLF5 expression.